Quick answers
- What is Atoltivimab, maftivimab, and odesivimab-ebgn used for?
- The FDA-approved label (Inmazeb, Regeneron Pharmaceuticals, Inc., December 15, 2025) says: “INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection […]. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Atoltivimab, maftivimab, and odesivimab-ebgn?
- The “Adverse Reactions” section of the FDA label (Inmazeb, Regeneron Pharmaceuticals, Inc., December 15, 2025) begins: “The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions Including Infusion-Associated Events [see Warnings and Precautions (5.1)] The most common adverse events (incidence ≥20%) were pyrexia, chills, tachycardia, tachypnea, and vomiting.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the drug interactions of Atoltivimab, maftivimab, and odesivimab-ebgn?
- The “Drug Interactions” section of the FDA label (Inmazeb, Regeneron Pharmaceuticals, Inc., December 15, 2025) begins: “Interaction with live vaccine indicated for prevention of Orthoebolavirus zairense infection: No vaccine interaction studies have been performed. INMAZEB may reduce the efficacy of the live vaccine. The interval between live vaccination following initiation of INMAZEB therapy should be in accordance with current vaccination guidelines. (7.1) 7.1 Vaccine Interactions No vaccine-therapeutic interaction studies have been performed in human subjects using INMAZEB.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Atoltivimab, maftivimab, and odesivimab-ebgn have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Atoltivimab, maftivimab, and odesivimab-ebgn?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Atoltivimab, maftivimab, and odesivimab-ebgn been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Atoltivimab, maftivimab, and odesivimab-ebgn?
- 1 company lists prescription products of Atoltivimab, maftivimab, and odesivimab-ebgn in the FDA NDC Directory, including Regeneron Pharmaceuticals, Inc.
What Atoltivimab, maftivimab, and odesivimab-ebgn is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection […]. …
— FDA label: Inmazeb, Regeneron Pharmaceuticals, Inc., effective December 15, 2025. Read the full label on DailyMed →
Label quoted: the one for the most common form (injection, solution, intravenous), Inmazeb, Regeneron Pharmaceuticals, Inc.; it covers 2 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Atoltivimab, maftivimab, and odesivimab-ebgn side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions Including Infusion-Associated Events [see Warnings and Precautions (5.1)] The most common adverse events (incidence ≥20%) were pyrexia, chills, tachycardia, tachypnea, and vomiting.
Read more of this section
(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Regeneron at 1-844-734-6643 or www.regeneron.com/contact or FDA AT 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates may not reflect the rates observed in practice. Overall, 382 adult and pediatric subjects with Orthoebolavirus zairense infection received INMAZEB in one clinical trial (the PALM trial) and as part of an expanded access program conducted in the Democratic Republic of Congo during a Orthoebolavirus zairense outbreak in 2018-2019. In the PALM trial, the safety of INMAZEB was evaluated in a multi-center, open-label, randomized controlled trial, in which 154 subjects (115 adult subjects and 39 pediatric subjects) received INMAZEB [50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg (3 mL/kg)] intravenously as a single infusion and 168 subjects received an investigational control [see Clinical Studies (14)]. All subjects received optimized standard of care treatment. During the same outbreak, INMAZEB [50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg (3 mL/kg)] was given to 228 subjects (190 adult subjects and 38 pediatric subjects) in the expanded access program. The safety data described below is derived from the PALM trial. Table 4 summarizes adverse events that were reported during INMAZEB infusion. The evaluation of adverse events in subjects who received INMAZEB may have been confounded by the signs and symptoms of the underlying Orthoebolavirus zairense infection. The most common adverse events reported in at least 20% of subjects who received INMAZEB were pyrexia (or elevation in fever), chills, tachycardia, tachypnea, and vomiting. The adverse event profile in adult and pediatric subjects treated with INMAZEB was similar. Table 4: Adverse Events That Occurred during INMAZEB Infusion in ≥10% of Adult and Pediatric Subjects in the PALM Trial Adverse Event Adverse events in this table were reported as preferred terms from a list of pre-defined or other adverse events that occurred on the day of infusion, and included signs and symptoms that occurred during or immediately after infusion INMAZEB (N=154) % Control Investigational therapy administered as three separate infusions (N=168) % Pyrexia (Elevation in fever) 54 58 Chills 39 33 Tachycardia 20 32 Tachypnea 19 28 Vomiting Adverse events that were not pre-specified 19 23 Hypotension 15 31 Diarrhea 11 18 Hypoxia 10 11 The following pre-specified symptoms, which were assessed on a daily basis while admitted to the treatment unit, were reported in 40% or more of subjects who received INMAZEB: diarrhea, pyrexia, and vomiting.
Table from the label
| Adverse EventAdverse events in this table were reported as preferred terms from a list of pre-defined or other adverse events that occurred on the day of infusion, and included signs and symptoms that occurred during or immediately after infusion | INMAZEB (N=154) % | ControlInvestigational therapy administered as three separate infusions (N=168) % |
|---|---|---|
| Pyrexia (Elevation in fever) | 54 | 58 |
| Chills | 39 | 33 |
| Tachycardia | 20 | 32 |
| Tachypnea | 19 | 28 |
| VomitingAdverse events that were not pre-specified | 19 | 23 |
| Hypotension | 15 | 31 |
| Diarrhea | 11 | 18 |
| Hypoxia | 10 | 11 |
— FDA label: Inmazeb, Regeneron Pharmaceuticals, Inc., effective December 15, 2025. This is part of the section. Read the full label on DailyMed →
Atoltivimab, maftivimab, and odesivimab-ebgn drug interactions
Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.
Interaction with live vaccine indicated for prevention of Orthoebolavirus zairense infection: No vaccine interaction studies have been performed. INMAZEB may reduce the efficacy of the live vaccine. The interval between live vaccination following initiation of INMAZEB therapy should be in accordance with current vaccination guidelines. (7.1) 7.1 Vaccine Interactions No vaccine-therapeutic interaction studies have been performed in human subjects using INMAZEB.
Read more of this section
However, because of the potential for INMAZEB to inhibit replication of a live vaccine virus indicated for prevention of Orthoebolavirus zairense infection and possibly reduce the efficacy of the vaccine, avoid the concurrent administration of a live vaccine during treatment with INMAZEB. The interval between live vaccination following initiation of INMAZEB therapy should be in accordance with current vaccination guidelines. The efficacy of INMAZEB among subjects who reported receipt of a recombinant live vaccine prior to their enrollment in the PALM clinical trial was similar to subjects who did not receive a vaccine.
— FDA label: Inmazeb, Regeneron Pharmaceuticals, Inc., effective December 15, 2025. Read the full label on DailyMed →
Atoltivimab, maftivimab, and odesivimab-ebgn dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
The recommended dosage of INMAZEB is 50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg diluted and administered as a single intravenous infusion. (2.1) Refer to the Full Prescribing Information for information on preparation and administration. (2.2) 2.1 Recommended Dosage INMAZEB is a combination of three human monoclonal antibodies co-formulated in a 1:1:1 ratio of atoltivimab, maftivimab, and odesivimab.
Read more of this section
INMAZEB is available as two different strength presentations, containing either 16.67 mg of each antibody per mL or 33.33 mg of each antibody per mL [see Dosage Forms and Strengths (3)]. The recommended dosage of INMAZEB is 50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg diluted and administered as a single intravenous infusion as shown in Table 1 [see Dosage and Administration (2.2)]. 2.2 Preparation and Administration INMAZEB must be prepared and administered under the supervision of a healthcare provider. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. INMAZEB should be clear to slightly opalescent, colorless to pale yellow solution that is free from visible particulates. Discard the vial if the solution is cloudy, discolored or contains particulate matter. Preparation for Intravenous Infusion The recommended dosage is based on 50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg. For example, a patient weighing 50 kg the recommended dosage is 2,500 mg of atoltivimab, 2,500 mg of maftivimab, and 2,500 mg of odesivimab. Determine the number of vials needed based on the calculated dose in volume (mL). – The number of vials needed depends on the INMAZEB strength used. Refer to Table 1 for the corresponding volume per kg needed to withdraw from each available strength presentation to prepare dose. – Multiple INMAZEB vials may be needed. Each vial contains 14.5 mL of INMAZEB solution, regardless of the strength presentation. For example, for a 50 kg patient, the volume of INMAZEB needed is 150 mL (11 vials) if using the 16.67 mg/16.67 mg/16.67 mg per mL solution or 75 mL (6 vials) if using the 33.33 mg/33.33 mg/33.33 mg per mL solution. Table 1: INMAZEB Dosage (Volume per kg) for Intravenous Infusion Preparation When Using the When Using the 241.7 mg of atoltivimab, 241.7 mg of maftivimab, and 241.7 mg of odesivimab per 14.5 mL 483.3 mg of atoltivimab, 483.3 mg of maftivimab, and 483.3 mg of odesivimab per 14.5 mL (16.67 mg /16.67 mg /16.67 mg per mL) Solution (33.33 mg/33.33 mg /33.33 mg per mL) Solution Withdraw 3 mL of solution per kg to prepare the dose Withdraw 1.5 mL of solution per kg to prepare the dose Do not shake the vial. Prior to intravenous infusion, INMAZEB must be further diluted in an intravenous PVC infusion bag containing either 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, or Lactated Ringer's Injection, USP. For neonates, the INMAZEB solution should be diluted in 5% Dextrose Injection, USP (see Table 2). The total volume of the infusion solution to be administered is based on the patient's body weight and is specified in Table 2.
Table from the label
| When Using the | When Using the |
|---|---|
| 241.7 mg of atoltivimab, 241.7 mg of maftivimab, and 241.7 mg of odesivimab per 14.5 mL | 483.3 mg of atoltivimab, 483.3 mg of maftivimab, and 483.3 mg of odesivimab per 14.5 mL |
| (16.67 mg /16.67 mg /16.67 mg per mL) Solution | (33.33 mg/33.33 mg /33.33 mg per mL) Solution |
| Withdraw 3 mL of solution per kg to prepare the dose | Withdraw 1.5 mL of solution per kg to prepare the dose |
— FDA label: Inmazeb, Regeneron Pharmaceuticals, Inc., effective December 15, 2025. This is part of the section. Read the full label on DailyMed →
Atoltivimab, maftivimab, and odesivimab-ebgn in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Risk Summary Orthoebolavirus zairense infection is life-threatening for both the mother and fetus and treatment should not be withheld due to pregnancy (see Clinical Considerations).
Read more of this section
Available data from the PALM trial and an expanded access program in which pregnant women with Orthoebolavirus zairense infection were treated with INMAZEB demonstrate the high rate of maternal and fetal/neonatal morbidity consistent with published literature regarding the risk associated with underlying maternal Orthoebolavirus zairense infection. These data are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal/fetal outcome. Animal reproduction studies with INMAZEB have not been conducted. Human monoclonal antibodies, such as INMAZEB, are transported across the placenta; therefore, INMAZEB has the potential to be transferred from the mother to the developing fetus. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Maternal, fetal and neonatal outcomes are poor among pregnant women infected with Orthoebolavirus zairense. The majority of such pregnancies result in maternal death with miscarriage, stillbirth, or neonatal death. Treatment should not be withheld due to pregnancy.
— FDA label: Inmazeb, Regeneron Pharmaceuticals, Inc., effective December 15, 2025. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Injection, solution |
|---|---|
| Route | Intravenous |
| Prescription products | 2 in the FDA NDC Directory |
| Brand names | Inmazeb |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Regeneron Pharmaceuticals, Inc.2 products
FDA approval history
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| BLA761169 INMAZEB | Regeneron Pharmaceuticals | October 14, 2020 | 3, latest October 24, 2024 2024: Labeling · 2022: Labeling · 2021: Manufacturing (CMC) |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 2461536, 2461539, 2571682, 2571685 |
|---|---|
| SPL set ID of the quoted label | 0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa |
| FDA labels (SPL) | 1 |
| FDA applications | BLA761169 |
| Active ingredients (FDA) | ATOLTIVIMAB / MAFTIVIMAB / ODESIVIMAB |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- Regeneron Pharmaceuticals, Inc.Maker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Inmazeb, Regeneron Pharmaceuticals, Inc., effective December 15, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →